Pathogenetic Mechanism | Counteragent |
---|---|
P-selectin inhibition | Crizanlizumab |
Polymerization | Voxelotor |
Upregulation of fetal hemoglobin production | Hydroxyurea Butyrate 5-Azacytidine, Decitabine |
Oxidative stress | L-glutamine |
Genetic mutation | CRISPR/Cas 9 technology and transplantation |
Abnormal rheology | Poloxamer 188 |
CRISPR/Cas 9, clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9.